 | • レポートコード：C-PMR-JN055 • 出版社/出版日：Persistence Market Research / 2018年10月 • レポート形態：英文、PDF、219ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：ライフサイエンス・トランスフォーメーションヘルス |
| Individual（１名、印刷不可） | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Multi User（５名） | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Corporate User | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
Persistence Market Research (PMR) offers an eight year forecast on the global immune repertoire sequencing market. The primary objective of the report is to offer updates and information related to the opportunities in the immune repertoire sequencing market.
Report Description
In terms of revenue, the global immune repertoire sequencing market is expected to register a CAGR of 7.3% during the forecast period, 2018–2028. The primary objective of the report is to offer insights on the market dynamics that can influence the growth of the global immune repertoire sequencing market over the forecast period. Insights on the key trends, drivers, restraints, value forecasts and opportunities for the companies operating in the global immune repertoire sequencing market are presented in the report.
The global market for immune repertoire sequencing is expected to witness high growth in terms of value in Asian countries due to substantial price drop in sequencing platforms and integration of new technologies in biomedical research including advancement in genome sequencing. In addition, increasing international collaboration in immune repertoire sequencing projects by other developing nations is also expected to drive the growth of the immune repertoire sequencing market.
The report includes immune repertoire sequencing component types such as assay kits, software (including software integrated system platforms) and services. However, the report does not include revenue generated by the instruments or devices (running without integrated software) and accessories incurred in various academic institutions and research centres. Revenues of third-party service vendors or representatives of primary service providers are excluded in the report. Besides, the currency fluctuations and inflation are not considered while calculating the revenue of the global immune repertoire sequencing market.
To understand and assess the opportunities in this market, the report offers the market forecast on the basis of segment type classified into the component type, application, end users and regions. The report provides analysis of the global immune repertoire sequencing market in terms of market value (US$ Mn).
By component type, the global immune repertoire sequencing market is segmented into:
Assay Kits
TCR Kits
BCR Kits
Software & Services
Analytical Software
Sequencing Services
Data Analysis Services
The report begins with the definition of immune repertoire sequencing, followed by definitions of different product types. The market dynamics section includes PMR’s analysis on the key trends, drivers, restraints, opportunities, macro-economic factors and key market strategies influencing the growth of the global immune repertoire sequencing market.
The report analyses the immune repertoire sequencing market on the basis of application type and end users and presents forecast in terms of value for the next 10 years. On the basis of application, the global immune repertoire sequencing market is segmented into:
Biomarker Discovery
Infectious Diseases
Vaccine Development and efficacy
Cancer Immunotherapy
Autoimmune Disease
Transplant Rejection and Tolerance
Others
On the basis of the end users, the global immune repertoire sequencing market is segmented into:
Academic Institutes
Research Centers Diagnostic laboratories
Next, the report analyses the market on the basis of regions and presents forecast in terms of value for the next 10 years. On the basis of region, the global immune repertoire sequencing market is segmented into:
North America
U.S.
Canada
Latin America
Brazil
Mexico
Rest of Latin America
Europe
Germany
France
U.K.
Italy
Spain
Poland
Russia
Rest of Eastern Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia- Pacific
Middle East & Africa (MEA)
GCC countries
South Africa
Rest of Middle East and Africa
In addition, we have considered the Year-on-Year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the global immune repertoire sequencing market.
Another key feature of this report is the analysis of the key segments in immune repertoire sequencing market in terms of absolute dollar opportunity. This is usually overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered in the global immune repertoire sequencing market. To understand the key segments in terms of their growth and performance in the global immune repertoire sequencing market, PMR has developed a market attractiveness index. The resulting index will help identify the existing opportunities in the global immune repertoire sequencing market.
In the final section of the report, the ‘competitive landscape’ has been included to provide a dashboard view of the key companies operating in the global immune repertoire sequencing market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of the key provider’s specific to a market segment in the global immune repertoire sequencing market. However, this section also includes market strategies and SWOT analysis of the key players operating in the global immune repertoire sequencing market.
Detailed profiles of the assay kit manufacturers, software and service providers of immune repertoire sequencing are also included in the scope of the report to evaluate their long- and short-term strategies. Examples of some of the key players operating in the global immune repertoire sequencing market are Illumina, Takara Bio Inc, BGI, Thermo Fischer Scientific, and F. Hoffmann-La Roche Ltd, among others.
レポート目次1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
3. Immune Repertoire Sequencing Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Market Background
4.1. Market Dynamics
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunity
4.1.4. Trends
5. Global Economic Outlook
5.1. Gross Domestic Product by Region & Country, 2006 – 2021
5.2. Global Healthcare Market Outlook
6. Key Inclusions
6.1. Product Mapping
6.2. Key Developments
6.3. Regional Average Pricing Analysis (2017)
7. North America Immune Repertoire Sequencing Market Analysis 2013–2017 and Forecast 2018–2026
7.1. Introduction
7.2. Historical Market Value (US$ Mn) Trend Analysis By Country, 2013–2017
7.2.1. U.S.
7.2.2. Canada
7.3. Market Value (US$ Mn) Forecast By Country, 2018–2026
7.4. Historical Market Value (US$ Mn) and By Component, 2012-2016
7.4.1. Assay Kits
7.4.1.1. TCR Kits
7.4.1.2. BCR Kits
7.4.2. Software & Services
7.4.2.1. Analytical Software
7.4.2.2. Sequencing Services
7.4.2.3. Data Analysis Services
7.5. Market Value (US$ Mn) and Forecast By Component, 2018-2026
7.6. Historical Market Value(US$ Mn) By Application, 2012-2016
7.6.1. Biomarker Discovery
7.6.2. Infectious Diseases
7.6.3. Vaccine Development and efficacy
7.6.4. Cancer Immunotherapy
7.6.5. Autoimmune Disease
7.6.6. Transplant Rejection and Tolerance
7.6.7. Others
7.7. Market Value (US$ Mn) Forecast By Application, 2018-2026
7.8. Historical Market Value (US$ Mn) By End user, 2012-2016
7.8.1. Academic Institutes
7.8.2. Research Centers
7.9. Market Value (US$ Mn) Forecast By End user,2018-2026
7.10. Market Attractiveness Analysis
7.10.1. By Country
7.10.2. By Component
7.10.3. By Application
7.10.4. By End user
7.11. Drivers and Restraints: Impact Analysis
8. Latin America Immune Repertoire Sequencing Market Analysis 2013–2017 and Forecast 2018–2026
8.1. Introduction
8.2. Key Regulations
8.3. Regional Market Dynamics
8.3.1. Drivers
8.3.2. Restraints
8.3.3. Trends
8.4. Historical Market Size (US$ Mn) and By Country, 2012-2016
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Market Size (US$ Mn) and Forecast By Country, 2018-2026
8.6. Historical Market Value (US$ Mn) and By Component, 2012-2016
8.6.1. Assay Kits
8.6.1.1. TCR Kits
8.6.1.2. BCR Kits
8.6.2. Software & Services
8.6.2.1. Analytical Software
8.6.2.2. Sequencing Services
8.6.2.3. Data Analysis Services
8.7. Market Value (US$ Mn) and Forecast By Component, 2018-2026
8.8. Historical Market Value (US$ Mn) By Application, 2012-2016
8.8.1. Biomarker Discovery
8.8.2. Infectious Diseases
8.8.3. Vaccine Development and efficacy
8.8.4. Cancer Immunotherapy
8.8.5. Autoimmune Disease
8.8.6. Transplant Rejection and Tolerance
8.8.7. Others
8.9. Market Value (US$ Mn) Forecast By Application, 2018-2026
8.10. Historical Market Value (US$ Mn) By End user, 2012-2016
8.10.1. Academic Institutes
8.10.2. Research Centers
8.11. Market Value (US$ Mn) Forecast By End user, 2018-2026
8.12. Market Attractiveness Analysis
8.12.1. By Country
8.12.2. By Component
8.12.3. By Application
8.12.4. By End user
8.13. Drivers and Restraints: Impact Analysis
9. Europe Immune Repertoire Sequencing Market Analysis 2013–2017 and Forecast 2018–2026
9.1. Introduction
9.2. Key Regulations
9.3. Regional Market Dynamics
9.3.1. Drivers
9.3.2. Restraints
9.3.3. Trends
9.4. Historical Market Size (US$ Mn) and By Country, 2012-2016
9.4.1. Germany
9.4.2. U.K.
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Poland
9.4.7. Russia
9.4.8. Rest of Europe
9.5. Market Size (US$ Mn) and Forecast By Country, 2018-2026
9.6. Historical Market Value (US$ Mn) and By Component, 2012-2016
9.6.1. Assay Kits
9.6.1.1. TCR Kits
9.6.1.2. BCR Kits
9.6.2. Software & Services
9.6.2.1. Analytical Software
9.6.2.2. Sequencing Services
9.6.2.3. Data Analysis Services
9.7. Market Value (US$ Mn) and Forecast By Component, 2018-2026
9.8. Historical Market Value(US$ Mn) By Application, 2012-2016
9.8.1. Biomarker Discovery
9.8.2. Infectious Diseases
9.8.3. Vaccine Development and efficacy
9.8.4. Cancer Immunotherapy
9.8.5. Autoimmune Disease
9.8.6. Transplant Rejection and Tolerance
9.8.7. Others
9.9. Market Value (US$ Mn) Forecast By Application, 2018-2026
9.10. Historical Market Value (US$ Mn) By End user, 2012-2016
9.10.1. Academic Institutes
9.10.2. Research Centers
9.11. Market Value (US$ Mn) Forecast By End user, 2018-2026
9.12. Market Attractiveness Analysis
9.12.1. By Country
9.12.2. By Component
9.12.3. By Application
9.12.4. By End user
9.13. Drivers and Restraints: Impact Analysis
10. Asia Pacific (APAC) Immune Repertoire Sequencing Market Analysis 2013–2017 and Forecast 2018–2026
10.1. Introduction
10.2. Key Regulations
10.3. Regional Market Dynamics
10.3.1. Drivers
10.3.2. Restraints
10.3.3. Trends
10.4. Historical Market Size (US$ Mn) and By Country, 2012-2016
10.4.1. China
10.4.2. India
10.4.3. Japan
10.4.4. Australia and New Zealand
10.4.5. Rest of APAC
10.5. Market Size (US$ Mn) and Forecast By Country, 2018-2026
10.6. Historical Market Value (US$ Mn) and By Component, 2012-2016
10.6.1. Assay Kits
10.6.1.1. TCR Kits
10.6.1.2. BCR Kits
10.6.2. Software & Services
10.6.2.1. Analytical Software
10.6.2.2. Sequencing Services
10.6.2.3. Data Analysis Services
10.7. Market Value (US$ Mn) and Forecast By Component, 2018-2026
10.8. Historical Market Value (US$ Mn) By Application, 2012-2016
10.8.1. Biomarker Discovery
10.8.2. Infectious Diseases
10.8.3. Vaccine Development and efficacy
10.8.4. Cancer Immunotherapy
10.8.5. Autoimmune Disease
10.8.6. Transplant Rejection and Tolerance
10.8.7. Others
10.9. Market Value (US$ Mn) Forecast By Application, 2018-2026
10.10. Historical Market Value (US$ Mn) By End user, 2012-2016
10.10.1. Academic Institutes
10.10.2. Research Centers
10.11. Market Value (US$ Mn) Forecast By End user,2018-2026
10.12. Market Attractiveness Analysis
10.12.1. By Country
10.12.2. By Component
10.12.3. By Application
10.12.4. By End user
10.13. Drivers and Restraints: Impact Analysis
11. Middle East and Africa (MEA) Immune Repertoire Sequencing Market Analysis 2013–2017 and Forecast 2018–2026
11.1. Introduction
11.2. Key Regulations
11.3. Regional Market Dynamics
11.3.1. Drivers
11.3.2. Restraints
11.3.3. Trends
11.4. Historical Market Size (US$ Mn) and By Country, 2012-2016
11.4.1. GCC Countries
11.4.2. South Africa
11.4.3. Rest of MEA
11.5. Market Size (US$ Mn) and Forecast By Country, 2018-2026
11.6. Historical Market Value (US$ Mn) and By Component, 2012-2016
11.6.1. Assay Kits
11.6.1.1. TCR Kits
11.6.1.2. BCR Kits
11.6.2. Software & Services
11.6.2.1. Analytical Software
11.6.2.2. Sequencing Services
11.6.2.3. Data Analysis Services
11.7. Market Value (US$ Mn) and Forecast By Component, 2018-2026
11.8. Historical Market Value(US$ Mn) By Application, 2012-2016
11.8.1. Biomarker Discovery
11.8.2. Infectious Diseases
11.8.3. Vaccine Development and efficacy
11.8.4. Cancer Immunotherapy
11.8.5. Autoimmune Disease
11.8.6. Transplant Rejection and Tolerance
11.8.7. Others
11.9. Market Value (US$ Mn) Forecast By Application, 2018-2026
11.10. Historical Market Value (US$ Mn) By End user, 2012-2016
11.10.1. Academic Institutes
11.10.2. Research Centers
11.11. Market Value (US$ Mn) Forecast By End user,2018-2026
11.12. Market Attractiveness Analysis
11.12.1. By Country
11.12.2. By Component
11.12.3. By Application
11.12.4. By End user
11.13. Drivers and Restraints: Impact Analysis
12. Forecast Factors: Relevance and Impact
13. Market Structure Analysis
13.1. Market Structure by Tier Companies
13.2. Competition Dashboard
13.3. Market Share Analysis (2017) by Global level
14. Competition Profile
14.1. Company Deep Dive
14.1.1. Illumina, Inc.
14.1.1.1. Overview
14.1.1.2. Key Financials
14.1.1.3. Product and Application Portfolio
14.1.1.4. Key Developments
14.1.1.5. Strategy
14.1.1.5.1.1. Marketing Strategy
14.1.1.5.1.2. Product Strategy
14.1.1.5.1.3. Channel Strategy
14.1.2. Pacific Biosciences of California, Inc
14.1.2.1. Overview
14.1.2.2. Key Financials
14.1.2.3. Product and Application Portfolio
14.1.2.4. Key Developments
14.1.2.5. Strategy
14.1.2.5.1.1. Marketing Strategy
14.1.2.5.1.2. Product Strategy
14.1.2.5.1.3. Channel Strategy
14.1.3. Agilent Technologies, Inc
14.1.3.1. Overview
14.1.3.2. Key Financials
14.1.3.3. Product and Application Portfolio
14.1.3.4. Key Developments
14.1.3.5. Strategy
14.1.3.5.1.1. Marketing Strategy
14.1.3.5.1.2. Product Strategy
14.1.3.5.1.3. Channel Strategy
14.1.4. Oxford Nanopore Technologies, Ltd
14.1.4.1. Overview
14.1.4.2. Product and Application Portfolio
14.1.4.3. Key Developments
14.1.4.4. Strategy
14.1.4.4.1.1. Marketing Strategy
14.1.4.4.1.2. Product Strategy
14.1.4.4.1.3. Channel Strategy
14.1.5. QIAGEN N.V.
14.1.5.1. Overview
14.1.5.2. Key Financials
14.1.5.3. Product and Application Portfolio
14.1.5.4. Key Developments
14.1.5.5. Strategy
14.1.5.5.1.1. Marketing Strategy
14.1.5.5.1.2. Product Strategy
14.1.5.5.1.3. Channel Strategy
14.1.6. Thermo Fisher Scientific
14.1.6.1. Overview
14.1.6.2. Key Financials
14.1.6.3. Product and Application Portfolio
14.1.6.4. Key Developments
14.1.6.5. Strategy
14.1.6.5.1.1. Marketing Strategy
14.1.6.5.1.2. Product Strategy
14.1.6.5.1.3. Channel Strategy
14.1.7. F. Hoffmann-La Roche Ltd
14.1.7.1. Overview
14.1.7.2. Key Financials
14.1.7.3. Product and Application Portfolio
14.1.7.4. Key Developments
14.1.7.5. Strategy
14.1.7.5.1.1. Marketing Strategy
14.1.7.5.1.2. Product Strategy
14.1.7.5.1.3. Channel Strategy
14.1.7.5.1.4. Channel Strategy
14.1.8. BGI
14.1.8.1. Overview
14.1.8.2. Product and Application Portfolio
14.1.8.3. Key Developments
14.1.8.4. Strategy
14.1.8.4.1.1. Marketing Strategy
14.1.8.4.1.2. Product Strategy
14.1.8.4.1.3. Channel Strategy
14.1.8.4.1.4. Channel Strategy
14.1.9. Takara Bio, Inc
14.1.9.1. Overview
14.1.9.2. Key Financials
14.1.9.3. Product and Application Portfolio
14.1.9.4. Key Developments
14.1.9.5. Strategy
14.1.9.5.1.1. Marketing Strategy
14.1.9.5.1.2. Product Strategy
14.1.9.5.1.3. Channel Strategy
14.1.9.5.1.4. Channel Strategy
15. Global Immune Repertoire Sequencing Market Analysis 2013–2017 and Forecast 2018–2026, By Region
15.1. Introduction
15.1.1. Basis Point Share (BPS) Analysis By Region
15.1.2. Y-o-Y Growth Projections By Region
15.2. Historical Market Value Analysis 2013–2017, By Region
15.2.1. North America
15.2.2. Latin America
15.2.3. Europe
15.2.4. Asia Pacific (APAC)
15.2.5. Middle East and Africa (MEA)
15.3. Market Value Analysis 2018–2026, By Region
15.3.1. North America
15.3.2. Latin America
15.3.3. Europe
15.3.4. Asia Pacific (APAC)
15.3.5. Middle East and Africa (MEA)
15.4. Market Attractiveness Analysis By Region
16. Global Immune Repertoire Sequencing Market Analysis 2013–2017 and Forecast 2018–2026, By Component
16.1. Introduction
16.1.1. Basis Point Share (BPS) Analysis By Component
16.1.2. Y-o-Y Growth Projections By Component
16.2. Historical Market Value Analysis 2013–2017, By Component
16.2.1. Assay Kits
16.2.1.1. TCR Kits
16.2.1.2. BCR Kits
16.2.2. Software & Services
16.2.2.1. Analytical Software
16.2.2.2. Sequencing Services
16.2.2.3. Data Analysis Services
16.3. Market Value Analysis 2017–2015, By Component
16.4. Market Attractiveness Analysis By Component
17. Global Immune Repertoire Sequencing Market Analysis 2013–2017 and Forecast 2018–2026, By Applications
17.1. Introduction
17.1.1. Basis Point Share (BPS) Analysis By Applications
17.1.2. Y-o-Y Growth Projections By Applications
17.2. Historical Market Value Analysis 2013–2017, By Applications
17.2.1. Biomarker Discovery
17.2.2. Infectious Diseases
17.2.3. Vaccine Development and efficacy
17.2.4. Cancer Immunotherapy
17.2.5. Autoimmune Disease
17.2.6. Transplant Rejection and Tolerance
17.2.7. Others
17.3. Historical Market Value Analysis 2018–2026, By Applications
17.4. Market Attractiveness Analysis By Applications
18. Global Immune Repertoire Sequencing Market Analysis 2013–2017 and Forecast 2018–2026, By End User
18.1. Introduction
18.1.1. Basis Point Share (BPS) Analysis By End User
18.1.2. Y-o-Y Growth Projections By End User
18.2. Historical Market Value Analysis 2013–2017, By End User
18.2.1. Academic Institutes
18.2.2. Research Centers
18.3. Market Value Analysis 2018–2026, By End User
18.4. Market Attractiveness Analysis By End User
19. Global Immune Repertoire Sequencing Market Analysis 2013–2017 and Forecast 2017–2026
19.1. Market Size and Y-o-Y Growth
19.2. Absolute $ Opportunity
20. Assumptions and Acronyms Used
21. Research Methodology
List of TablesTable 01: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
Table 02: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
Table 03: Assay Kits Product Mapping
Table 04: Assay Kits Product Mapping
Table 05: Software Services Product Mapping
Table 06: Software Services Product Mapping
Table 07: Software Services Product Mapping
Table 08: Software & Services Product Mapping
Table 09: Software & Services Product Mapping
Table 10: Key Developments
Table 11: Key Developments
Table 12 : North America Immune Repertoire Sequencing Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 13 : North America Immune Repertoire Sequencing Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Component
Table 14 : North America Immune Repertoire Sequencing Market Size Analysis 2013-2017 and Forecast 2018-2026, By Application
Table 15 : North America Immune Repertoire Sequencing Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 16 : Latin America Immune Repertoire Sequencing Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 17 : Latin America Immune Repertoire Sequencing Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Component
Table 18 : Latin America Immune Repertoire Sequencing Market Size Analysis 2013-2017 and Forecast 2018-2026, By Application
Table 19 : Latin America Immune Repertoire Sequencing Market Size Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 20 : Europe Immune Repertoire Sequencing Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 21 : Europe Immune Repertoire Sequencing Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Component
Table 22 : Europe Immune Repertoire Sequencing Market Size Analysis 2013-2017 and Forecast 2018-2026, By Application
Table 23 : Europe Immune Repertoire Sequencing Market Size Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 24 : Asia Pacific Immune Repertoire Sequencing Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 25 : Asia Pacific Immune Repertoire Sequencing Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Component
Table 26 : Asia Pacific Immune Repertoire Sequencing Market Size Analysis 2013-2017 and Forecast 2018-2026, By Application
Table 27 : Asia Pacific Immune Repertoire Sequencing Market Size Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 28 : Middle East & Africa Immune Repertoire Sequencing Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 29 : Middle East & Africa Immune Repertoire Sequencing Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Component
Table 30 : Middle East & Africa Immune Repertoire Sequencing Market Size Analysis 2013-2017 and Forecast 2018-2026, By Application
Table 31 : Middle East & Africa Immune Repertoire Sequencing Market Size Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 32 : Global Immune Repertoire Sequencing Market Size (US$ Mn) 2013–2017 and Forecast 2018-2026 By Region
Table 33 : Global Market Size (US$ Mn) 2013–2017 and Forecast 2018-2026 By Component
Table 34 : Global Market Size (US$ Mn) 2013–2017 and Forecast 2018-2026 By Application
Table 35 : Global Market Size (US$ Mn) 2013–2017 and Forecast 2018-2026 By End User